Abstract
The Quality of Life after Treatment for Brain Metastases (QUARTZ) trial was a non-inferiority, phase III randomized trial comparing optimal supportive care (OSC) including dexamethasone versus OSC including dexamethasone and whole brain radiotherapy (WBRT). In this trial, 538 patients were recruited from 69 United Kingdom and three Australian centres. The primary outcome was quality-adjusted life-years (QALYs), generated from overall survival and patient completed EuroQOL EQ-5D questionnaires. The mean QALYs was 46.4 days for the OSC and WBRT arm versus 41.7 days for the OSC arm, with a mean difference of 4.7 days (90% CI: −12.7 to 3.3 days). In addition, there was no difference in overall survival (hazard ratio 1.06, 95% CI: 0.90–1.26), overall quality of life or dexamethasone use between the two groups (1).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
